Biocept, Inc. (OTCPK: BIOC.Q)
Health Care · Biotechnology · US
$—
— today · — 1Y
Biocept, Inc. (OTCPK: BIOC.Q) operates in the Biotechnology industry within the Health Care sector. The company is valued at $263.00 and employs 50 people.
trading between 0.00 and 0.10.
Tweenvest scores Biocept, Inc. across four factors: quality 36/100, value 47/100, growth 100/100. Its strongest factor is growth.
BIOC.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $263.00
- Revenue (TTM)
- $1.36M
- P/E
- —
- EPS
- -44.33
- Dividend yield
- —
- Beta (5Y)
- 68.75
- 52-week high
- $0.10
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.63M
- Employees
- 50
- Next earnings
- —
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
- ISIN
- US09072V6002
- Founded
- 1997
- Listed since
- Feb 5, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.66 | -0.11% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.19 | +0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.78 | -0.23% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.02 | -0.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $827.00 | -0.84% |
| argenx SEENXTBR: ARGX | $65.85B | €877.40 | -2.73% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $134.86 | -7.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.